Stereological Comparison of the Effects of Pentoxifylline, Captopril, Simvastatin, and Tamoxifen on Kidney and Bladder Structure After Partial Urethral Obstruction in Rats

Mehdi Shirazi1,2, Mohammad-Reza Soltani2, Zahra Jahanabadi2, Mohammad-Amin Abdollahifar1,3, Nader Tanideh4, Ali Noorafshan1

1Histomorphometry and Stereology Research Centre, Shiraz University of Medical Sciences, Shiraz, 2Department of Urology, Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, 3Anatomy Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, 4Stem Cell and Transgenic Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Purpose: Limited studies have shown antifibrotic effects of pentoxifylline, captopril, simvastatin, and tamoxifen. No comparisons are available of the effects of these drugs on prevention of renal and bladder changes in partial urethral obstruction (PUO).

Materials and Methods: The rats were divided into six groups (n=7). The sham-operated rats (group I) only underwent laparotomy and did not receive any treatments. The PUO groups (group II–VI) received normal saline (PUO+NS), pentoxifylline (100 mg/kg/d; PUO+PEN), captopril (35 mg/kg/d; PUO+CAP), simvastatin (15 mg/kg/d; PUO+SIM), or tamoxifen (10 mg/kg/d; PUO+TAM) by gavage for 28 days. Then, the volume and/or length of the kidney components (tubules, vessels, and fibrous tissue) and the bladder components (epithelial and muscular layers, fibrous tissue, fibroblast and fibrocyte number) were quantitatively evaluated on the microscopic sections by use of stereological techniques.

Results: The volume of renal and bladder fibrosis was significantly ameliorated in the PUO+PEN group, followed by the PUO+CAP, PUO+SIM, and PUO+TAM groups. Also, the volume and length of the renal tubules and vessels and bladder layers were more significantly protected in the PUO+PEN group, followed by the PUO+CAP, PUO+SIM, and PUO+TAM groups.

Conclusions: Treatment of PUO with PEN was more effective in the prevention of renal and bladder fibrosis and in the preservation of renal and bladder structures.

Keywords: Captopril; Pentoxifylline; Simvastatin; Tamoxifen; Urethral obstruction

INTRODUCTION

Bladder outlet obstruction is a relatively common urological problem that occurs as the result of congenital anomalies such as posterior urethral valve, benign prostatic hyperplasia, and urethral stricture [1]. Intravesical obstruction results in numerous changes in the upper and lower urinary tract, eventually leading to chronic renal failure [2-4]. Increased bladder outlet resistance also impairs the storage function and results in loss of bladder viscoelasticity secondary to fibrous proliferation and mucosa and collagen accumulation [2-4]. Although the explanations for bladder dysfunction are not fully understood, fetal urethral obstruction has been reported to result in deposition of an abnormal quantity of collagen in the bladder, which can play a major role in bladder hypocompliance [4]. Furthermore, chronic renal damage due to tubulointerstitial fibrosis is one of the adverse effects of bladder outlet obstruction [5-7]. Although the first-line treatment of bladder outlet obstruction is relief of the obstruction by surgery, some patients are not good candidates for operation. Therefore, attempts should be made to find the best medi-
cation for prevention of the structural changes of kidney and bladder. The present study aimed to investigate and compare the effects of tamoxifen, captopril, pentoxifylline, and simvastatin on prevention of renal and bladder fibrosis and damage in a rat model of partial urethral obstruction (PUO). Primarily, tamoxifen is an antiestrogen therapy for receptor-positive breast cancer, infertility, gynecomastia, and related diseases [8,9]. However, positive effects of tamoxifen have been observed in the treatment of retroperitoneal fibrosis and also in renal fibrosis [8,9]. Captopril is commonly prescribed as an angiotensin-converting enzyme inhibitor for the treatment of some medical conditions, including hypertension and some types of congestive heart failure [10,11]. The positive effect of captopril in amelioration of renal fibrosis has also been evaluated in previous studies [10,11]. Pentoxifylline mainly improves blood flow through peripheral blood vessels [12,13]. In addition, it has been shown that pentoxifylline can reduce tubulointerstitial fibrosis [12,13]. Simvastatin is primarily used for the treatment of dyslipidemia and the prevention of cardiovascular diseases. However, research has shown that after unilateral ureteral obstruction, renal fibrosis is reduced in simvastatin-treated animals [14,15]. To the best of our knowledge, no studies have compared the effects of these drugs on renal and bladder fibrosis. In addition, the microscopic structure of the kidney and bladder has not been compared quantitatively in PUO animals treated with the above-mentioned drugs. In the present study, this quantitative technique was used to measure the volume or length of the kidney components (its proximal and distal convoluted tubules [PCT and DCT], loop of Henle, collecting duct, and interstitial tissue) and bladder components (epithelium, muscular tissue, interstitial tissue, and number of fibroblasts and fibrocytes).

MATERIALS AND METHODS

1. Animals
This study was conducted on 42 male rats weighting 180±20 g. The animals were treated according to the standard directive recommended and approved by the research authorities of Shiraz University of Medical Sciences, Shiraz, Iran (approval no. 9101015143). The rats were randomly divided into six groups each including seven animals, which is considered to be an acceptable number for stereological studies [16]. The sham-operated animals underwent laparotomy only without undergoing any procedures or receiving any treatments. Other groups, however, underwent a surgery to induce PUO. The PUO groups received normal saline (PUO+NS), tamoxifen (10 mg/kg/d; PUO+TAM) [9], captopril (35 mg/kg/d; PUO+CAP) [10], pentoxifylline (100 mg/kg/d; PUO+PEN) [12], or simvastatin (15 mg/kg/d; PUO+SIM) [14] by gavage for 28 days. The doses selected were based on studies that confirmed the protective effects of these drugs in fibrosis.

2. Surgical procedure
After the rats were anesthetized with ketamine/xylazine (25 mg/kg intraperitoneally and 2.5 mg/kg intraperitoneally, respectively) in the supine position, the abdominal cavity was opened by a midline incision to reach the posterior urethra. Then, a pediatric 22-gauge Angiocath was introduced to the posterior urethra and a silk 4-0 ligature was tied around the Angiocath. Afterwards, the Angiocath was removed and PUO was induced. Finally, the incision was closed. The rats' kidneys and bladders were removed after 28 days.

3. Stereological study
At first, the rats' kidneys and bladders were removed and the renal pelvis was dissected out. Then, the kidney and bladder were weighed. The primary volume of the kidney, V(primary), was measured by using Sherle's immersion technique [17,18]. After that, the organs were fixed in neutral buffered formaldehyde for 1 week. Then, the tissue shrinkage produced by fixation, processing, and staining was estimated. Estimation of the shrinkage and length of the renal tubules as well as the vessels require isotropic uniform random sectioning [19,20]. These sections were obtained through the orientator method [19]. Then, two random circular pieces were punched out from the isotropic uniform random slabs. The estimated shrinkage was also used to estimate the final volume of the kidney or bladder to avoid the consecutive sectioning that is required for the Cavalieri method. Shrinkage degree was estimated by using the following formula [19]:

Shrinkage degree = 1−(AA/AB)1.5

where AA and AB are the area of the circular pieces after and before processing and staining, respectively. The pieces of kidney and bladder were embedded in separate paraffin blocks. After sectioning and staining, the sampled section was analyzed by using a video microscopy system. In doing so, 10 to 12 microscopic fields were sampled in a systematic random manner. Then, the stereological grids were superimposed on the images by means of the stereology software. The volume density of each structure (Vv; the fraction of the unit volume of the kidney or bladder that is occupied by the structural component) was estimated by using the point-counting method [19]. In addition, the volume fraction of the renal structures was estimated at a final magnification of ×1,500 by using the following formula:

Vv(component) = P(components)/P(reference)

where P(components) and P(reference) were the total number of the points hitting the favored components and the reference tissue (kidney or bladder), respectively. The total volume of the structural components was estimated by multiplying the volume density by the kidney or bladder volume [19].

Moreover, the length density (Lv: the length of each tubu-
Results

1. Volume of the kidney, tubules, and vessels

No significant differences were observed between the groups regarding the volume of the kidney, PCT, DCT, collecting duct, Henle’s loop, and vessels (Table 1).

2. Length of the renal tubules and vessels

The length of the PCT, DCT, collecting duct, Henle’s loop, and vessels, respectively, was reduced by 37%, 38%, 40%, 46%, and 23% in the PUO+NS rats compared with the sham-operated animals (p < 0.01). However, treatment of the PUO animals with pentoxifylline, tamoxifen, captopril, and simvastatin prevented the decrease in tubule and vessel length (Table 2) (p < 0.05). Pentoxifylline more significantly preserved the length of the renal tubules and vessels.

3. Volume of the bladder, epithelial tissue, and muscle tissues

The volume of the bladder, epithelial tissue, and muscle tissue was increased by 5- to 7-fold in the PUO+NS rats compared with the sham-operated animals (p < 0.01). Moreover, the volumes were lower in the PUO+PEN and PUO+SIM groups than in the PUO+NS rats (p < 0.05) (Table 3). In this respect, pentoxifylline was more effective than the other drugs.

4. Volume of fibrous tissue

The volume of the fibrous tissue was increased by 4- and 10-fold in the kidney and bladder of the PUO+NS rats compared with the sham-operated animals, respectively (p < 0.01). In addition, the volume of fibrous tissue in the PUO+PEN, PUO+CAP, and PUO+SIM rats was significantly lower than that in the PUO+NS group (p < 0.05) (Tables 1, 3).

5. Number of fibroblasts and fibrocytes

The number of fibroblasts and fibrocytes increased by 7.5-fold in the PUO+NS rats compared with the sham-operated rats.
The tubules seemed dilated. After treatment of the PUO, fibrous tissue was formed and replaced the tubular tissue. Normal saline treatment, normal tubular cells were lost. As can be seen from Fig. 1, in the PUO rats who received pharmacological treatment showed that more epithelial tissue can be seen. The muscle layer was hypertrophied. Fibrous tissue was increased in the different layers of the bladder. PUO+PEN ameliorated the changes in bladder structure, followed by CAP, SIM, and TAM.

6. Qualitative evaluation of the kidney and bladder

As can be seen from Fig. 1, in the PUO rats who received normal saline treatment, normal tubular cells were lost. Fibrous tissue was formed and replaced the tubular tissue. The tubules seemed dilated. After treatment of the PUO animals, the above-mentioned changes were ameliorated. In the PUO+PEN group, less fibrosis and more normal tubules and vessels could be found. These findings were followed by CAP, SIM, and TAM.

Evaluation of the bladder (Fig. 2) in the PUO group without pharmacological treatment showed that more epithelial tissue can be seen. The muscle layer was hypertrophied. Fibrous tissue was increased in the different layers of the bladder. PUO+PEN ameliorated the changes in bladder structure, followed by CAP, SIM, and TAM.

Values are presented as mean±standard deviation.

PCT, proximal convoluted tubule; DCT, distal convoluted tubule; CD, collecting ducts; LH, loop of Henle; NS, normal saline; TAM, tamoxifen; CAP, captopril; PEN, pentoxifylline; SIM, simvastatin; PUO, partial urethral obstruction.

| Group                      | Length (m)     |
|----------------------------|----------------|
|                            | PCT           | DCT           | CD            | LH            | Vessel         |
| Sham-operated              | 57.5±18.4'    | 41.3±12.5''   | 36.4±5.6''    | 33.0±10.0''   | 34.1±9.7''     |
| PUO+NS                     | 36.7±21.6"    | 25.6±141'     | 21.7±13.0'    | 17.6±10.3'    | 26.3±14.8'     |
| PUO+TAM                    | 59.3±22.8'    | 43.1±13.3'    | 41.7±9.6'     | 33.9±8.6'     | 38.6±9.4'      |
| PUO+CAP                    | 46.8±25.2'    | 33.7±8.4'     | 33.0±20.9'    | 27.2±12.5'    | 29.8±12.3'     |
| PUO+PEN                    | 63.1±24.3'†   | 54.1±27.1'†   | 46.4±20.9'†   | 40.7±16.8'†   | 45.8±20.4'†    |
| PUO+SIM                    | 40.9±20.0'    | 24.9±13.4'    | 34.3±16.3'    | 28.4±10.5'    | 33.0±15.2'     |

Values are presented as mean±standard deviation.

| Group                      | Weight (mg)     | Volume (mm³)      | No. of cells |
|----------------------------|-----------------|-------------------|--------------|
|                            | Bladder         | Epithelial        | Interstitial | Muscular     |
| Sham-operated              | 62.0±48.1"      | 72.0±8.3"        | 3.4±2.1"    | 33.7±4.7"    | 27.2±12.6"    | 133,325±162,764" |
| PUO+NS                     | 332.5±49.2"     | 327.5±84.2"      | 22.6±32.2"  | 345.4±239.2" | 187.6±144.0"  | 895,053±507,715" |
| PUO+TAM                    | 596.0±266.9"    | 556.0±260.8"     | 22.1±25.5"  | 294.1±158.7" | 216.0±120.6"  | 892,436±80,160" |
| PUO+CAP                    | 330.0±122.7"    | 302.5±119.8"     | 12.8±6.3"   | 95.3±80.5"   | 93.6±26.3"    | 512,128±98,776" |
| PUO+PEN                    | 163.3±114.1"†   | 155.0±104.8"†    | 7.5±8.8"†   | 59.1±51.1"†  | 67.4±30.7"†   | 208,760±26,343" |
| PUO+SIM                    | 271.6±165.4"    | 250.0±155.5"     | 9.1±55.0"   | 141.6±100.9" | 91.0±55.0"    | 626,864±97,137" |

DISCUSSION

The present study aimed to examine the effects of pentoxifylline, captopril, simvastatin, and tamoxifen on renal and bladder histological changes in rats after PUO. The first step of the study confirmed that PUO led to structural changes in the organs after a period of 28 days. It has been shown that bladder dysfunction secondary to PUO is characterized by bladder wall hypertrophy, decreased capacity and urinary stream, and increased postvoid residual urine [4-6,17,22]. If the obstruction is not relieved, the bladder enters the decompensating phase, in which detrusor contractility is decreased, eventually leading to hydronephrosis and renal damage [4-6,17,22]. These findings are in line with the findings of the present study. Hypertrophy of the bladder epithelium and muscular layer was seen in PUO rats. In addition, the injury extended to the kidney structure after 28 days. The results of the current study indicated a decrease in the length of the renal tubules and vessels after PUO. Decreased length should be considered a sign of renal tissue loss. Accompanying the loss of renal tissue, the fibrous tissue was increased after PUO, so that
FIG. 1. Micrograph of the kidney in the different groups. (A) Sham-operated animals with normal structure. (B) PUO+ normal saline treatment. The normal tubular cells are lost. Fibrous tissue was formed and replaced the tubular tissue. The tubules seemed dilated. (C) PUO+PEN, (D) PUO+CAP, (E) PUO+SIM, (F) PUO+TAM. Heidenhain’s AZAN trichrome stain (scale bar, 50 μm). PUO, partial urethral obstruction; PEN, pentoxifylline; CAP, captopril; SIM, simvastatin; TAM, tamoxifen.

the total volume and weight of the kidney did not change. It appears that two main questions were evaluated here: How much fibrous tissue formation can be prevented? How much intact tissue can be preserved? The current study confirmed that pentoxifylline, captopril, simvastatin, and tamoxifen could prevent fibrous tissue formation and pro-
FIG. 2. Micrograph of the bladder in the different groups. (A) Sham-operated animals with normal structure. (B) PUO+ NS, (C) PUO+PEN, (D) PUO+CAP, (E) PUO+SIM, (F) PUO+TAM. PUO without pharmacological treatment showed that more epithelial tissue can be seen. The muscle layer was hypertrophied. Fibrous tissue was increased in the different layers of the bladder. PUO+PEN ameliorated the changes in bladder structure followed by CAP, SIM, and TAM. Heidenhain's AZAN trichrome stain (scale bar, 250 μm). PUO, partial urethral obstruction; PEN, pentoxifylline; CAP, captopril; SIM, simvastatin; TAM, tamoxifen.
tected the renal tissue in PUO rats. It has been reported that an increase in angiotensin II levels in obstructive nephropathy up-regulates the expression of several factors, including transforming growth factor (TGF-β). Local production of TGF-β by macrophages penetrating the kidney is a key mediator of renal fibrosis [4]. Activation of TGF-β stimulates endothelin production, which in turn is a persuasive stimulus for fibrogenesis [4]. Therefore, if these mechanisms could be controlled, fibrous tissue formation would decrease, eventually preserving the normal renal and bladder histology after PUO. It has been shown that after obstruction, captopril not only decreases the angiotensin II and TGF-β levels but also inhibits conversion of procollagen to collagen in the interstitial space of the kidney.

Tamoxifen also has an antifibrotic effect by reducing TGF-β expression by fibroblasts [9]. Pentoxifylline has an inhibitory effect on neutrophil-mediated functions, such as superoxide production, chemotaxis, phagocytosis, and TNF production [18]. TNF-α has a substantial impact on molecular mechanisms, resulting in tubular cell death. Antifibrotic, anti-inflammatory, and anti-ischemic effects of pentoxifylline have also been mentioned in an earlier study [18]. Simvastatin also up-regulates the inhibitors of TGF-β signaling, attenuates epithelial-to-mesenchymal transition, and decreases renal fibrosis [14,15].

Moreover, our previous studies reported that administration of captopril could decrease interstitial fibrosis and preserve renal tubules after PUO [23]. In an animal model, Shirazi et al. [24] showed that captopril preserved the amount of renal tubules and tamoxifen decreased fibrous tissue formation in unilateral obstructed kidney. In another study, Shirazi et al. [12] also demonstrated that pentoxifylline could inhibit interstitial renal fibrosis after PUO.

CONCLUSIONS

In the rat model of PUO, pentoxifylline followed by captopril, simvastatin, and tamoxifen could prevent fibrous tissue formation and protect the renal tissue. Treatment with all the above-mentioned drugs prevented the decrease in tubular length and vessels, with pentoxifylline being the most effective. Moreover, bladder fibrosis was more significantly prevented by pentoxifylline followed by captopril and simvastatin. Also, bladder structure was more significantly protected by pentoxifylline followed by captopril and simvastatin. Therefore, pentoxifylline was most effective in preservation of renal and bladder structure after PUO.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

ACKNOWLEDGMENTS

This article was extracted from the thesis written by Dr. Mohammad-Reza Soltani for taking the degree in Urology. The work was carried out at the Histomorphometry and Stereology Research Center and was financially supported by the research Vice-Chancellor of Shiraz University of Medical Sciences, Shiraz, Iran (Grant No. 9101015143). Hereby, the authors would like to thank Ms. A. Keivanshekouh at the Research Improvement Center of Shiraz University of Medical Sciences for improving the use of English in the manuscript.

REFERENCES

1. Juan YS, Chuang SM, Jang MY, Huang CH, Chou YH, Wu WJ, et al. Basic research in bladder outlet obstruction. In: Pelvic Floor dysfunction 2011;5:1-6.
2. Tucci S Jr, Molina CA, Cassini MF, Andrade MF, Lima GJ, Martins AC. Chronic partial urethral obstruction in female rats: description of an experimental model and initial results. Acta Cir Bras 2011;26 Suppl 2:111-4.
3. Peters CA. Congenital bladder obstruction: research strategies and directions. Adv Exp Med Biol 1995;385:117-30.
4. Levin RM, Chichester P, Haas MA, Gosling JA, Buttyan R. Obstructive bladder dysfunction: morphological, biochemical and molecular changes. Eur Urol Suppl 2002;1:14-20.
5. Tseng YT, Stoller ML. Obstructive uropathy. Clin Geriatr Med 2009;25:437-43.
6. Hanai T, Ma FH, Matsumoto S, Park YC, Kurita T. Partial outlet obstruction of the rat bladder induces a stimulatory response on proliferation of the bladder smooth muscle cells. Int Urol Nephrol 2002;34:37-42.
7. Parkhouse HF, Barratt TM, Dillon MJ, Duffy PG, Fay J, Ransley PG, et al. Long-term outcome of boys with posterior urethral valves. Br J Urol 1988;62:59-62.
8. Dedegolu F, Rose CD, Athreya BH, Conard K, Grissom L, Magnusson M. Successful treatment of retroperitoneal fibrosis with tamoxifen in a child. J Rheumatol 2001;28:1693-5.
9. Delle H, Rocha JR, Cavaglieni RC, Vieira JM Jr, Malheiros DM, Noronha IL. Antifibrotic effect of tamoxifen in a model of progressive renal disease. J Am Soc Nephrol 2012;23:37-48.
10. Shirazi M, Noorafshan A, Bahri MA, Hassanpoor A. Captopril reduces deposition of collagen in lamina propria and muscular layers of the bladder and ureter in neonatal dogs with partial urethral obstruction. Scand J Urol Nephrol 2008;42:324-9.
11. Akbar DH, Hagras MM, Amin HA, Khorsheid OA. Comparison between the effect of glibenclamide and captopril on experimentally induced diabetic nephropathy in rats. J Renin Angiotens Aldosterone Syst 2013;14:103-15.
12. Shirazi M, Noorafshan A, Farrokh A. Effects of pentoxifylline on renal structure after urethral obstruction in rat: a stereological study. Cent European J Urol 2011;64:30-3.
13. Zhou GQ, Zheng FL, Hou FF. Inhibition of tubulointerstitial fibrosis by pentoxifylline is associated with improvement of vascular endothelial growth factor expression. Acta Pharmacol Sin 2009;30:98-106.
14. Acikgoz Y, Can B, Bek K, Acikgoz A, Ozkaya O, Genc G, et al. The effect of simvastatin and erythropoietin on renal fibrosis in rats with unilateral ureteral obstruction. Ren Fail 2014;36:252-7.
15. Vieira JM Jr, Mantovani E, Rodrigues LT, Delle H, Noronha IL, Fujibara CR, et al. Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrol Dial Transplant 2005;20:1582-91.
16. Weibel ER, Hsia CC, Ochs M. How much is there really? Why stereology is essential in lung morphometry. J Appl Physiol (1985) 2007;102:459-67.
17. Bajpai M, Pratap A, Tripathi M, Bal CS. Posterior urethral valves: preliminary observations on the significance of plasma Renin activity as a prognostic marker. J Urol 2005;173:592-4.
18. Chen YM, Chien CT, Hu-Tsai MI, Wu KD, Tsai CC, Wu MS, et al. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int 1999;56:932-43.
19. Nyengaard JR. Stereologic methods and their application in kidney research. J Am Soc Nephrol 1999;10:1100-23.
20. Karbalay-Doust S, Noorafshan A, Pourshahid SM. Taxol and taurine protect the renal tissue of rats after unilateral ureteral obstruction: a stereological survey. Korean J Urol 2012;53:360-7.
21. von Bartheld CS. Distribution of particles in the z-axis of tissue sections: relevance for counting methods. Neuroquantology 2012;10:66-75.
22. Egido J, Gomez-Chiarri M, Ortiz A, Bustos C, Alonso J, Gomez-Guerrero C, et al. Role of tumor necrosis factor-alpha in the pathogenesis of glomerular diseases. Kidney Int Suppl 1993;39:S59-64.
23. Shirazi M, Noorafshan A, Bahri MA, Tanideh N. Captopril reduces interstitial renal fibrosis and preserves more normal renal tubules in neonatal dogs with partial urethral obstruction: a preliminary study. Urol Int 2007;78:173-7.
24. Shirazi M, Noorafshan A, Kroup M, Tanideh N. Comparison of the effects of captopril, tamoxifen and L-carnitine on renal structure and fibrosis after total unilateral ureteral obstruction in the rat. Scand J Urol Nephrol 2007;41:91-7.